PATIENT REPORTED OUTCOMES AMONG PATIENTS RECEIVING TREATMENT FROM THE PEGLOTICASE PHASE 3 CLINICAL TRIALS FOR UNCONTROLLED GOUT

被引：1
|
作者：
Sparks, J. [1 ]
Obermeyer, K. [2 ]
Lamoreaux, B. [3 ]
机构：
[1] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA
[2] Horizon Therapeut Plc, Biostat, Deerfield, IL USA
[3] Horizon Therapeut Plc, Med Affairs, Deerfield, IL USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
QUALITY-OF-LIFE;
D O I：
10.1136/annrheumdis-2022-eular.1156
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB1039
引用
收藏
页码：1643 / 1643
页数：1
相关论文
共 50 条
  • [1] PHARMACOKINETICS OF PEGLOTICASE AND METHOTREXATE POLYGLUTAMATE(S) IN PATIENTS WITH UNCONTROLLED GOUT RECEIVING PEGLOTICASE AND CO-TREATMENT OF METHOTREXATE
    Song, Y.
    Xin, Y.
    Weinblatt, M. E.
    Chamberlain, J.
    Obermeyer, K.
    Zhao, L.
    Canavan, C.
    Peloso, P. M.
    Ramanathan, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 847 - 848
  • [2] PHARMACOKINETICS OF PEGLOTICASE AND METHOTREXATE POLYGLUTAMATE(S) IN PATIENTS WITH UNCONTROLLED GOUT RECEIVING PEGLOTICASE AND CO-TREATMENT WITH METHOTREXATE
    Xin, Y.
    Song, Y.
    Weinblatt, M. E.
    Chamberlain, J.
    Zarzoso, J.
    Obermeyer, K.
    Sainati, S.
    Canavan, C.
    Ramanathan, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 910 - 910
  • [3] PROTECT: PEGLOTICASE TREATMENT FOR UNCONTROLLED GOUT IN KIDNEY TRANSPLANTED PATIENTS; RESULTS FROM A PHASE 4 TRIAL
    Abdellatif, A.
    Zhao, L.
    Cherny, K.
    Marder, B.
    Scandling, J.
    Saag, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 908 - 909
  • [4] Treatment Failure Gout: Efficacy and Safety of Pegloticase in Phase 3 Trials.
    Sundy, John S.
    Becker, Michael S.
    Huang, William Y.
    Waltrip, Royce W.
    Chandraker, Anil K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 600 - 600
  • [5] Neutrophil-to-lymphocyte Ratio Among Flaring and Non-flaring Uncontrolled Gout Patients Undergoing Pegloticase Therapy as Part of the Phase 3 Pivotal Trials
    Pillinger, Michael
    Obermeyer, Katie
    Padnick-Silver, Lissa
    LaMoreaux, Brian
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3565 - 3566
  • [6] Patient reported outcomes associated with gout: Baseline results from two clinical trials.
    Osterhaus, JT
    Patel, P
    Palo, WA
    Bakst, A
    Joseph-Ridge, N
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S401 - S402
  • [7] THE ASSOCIATION BETWEEN PATIENT REPORTED OUTCOMES AND CLINICAL MEASURES AMONG RHEUMATOID ARTHRITIS PATIENTS: ANALYSES USING PHASE 3 CLINICAL TRIALS OF UPADACITINIB
    Strand, Vibeke
    Damjanov, Nemanja
    Scoville, Craig
    Tundia, Namita
    Camp, Heidi
    Chen, Kun
    Suboticki, Jessica L.
    van Vollenhoven, Ronald
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S54 - S54
  • [8] Clinical Efficacy Outcomes with up to 3 Years of Pegloticase Treatment for Refractory Chronic Gout.
    Becker, Michael A.
    Baraf, Herbert S. B.
    Yood, Robert A.
    Dillon, Aileen M.
    Vazquez-Mellado, Janitzia
    Ottery, Faith D.
    Khanna, Dinesh
    Sundy, John S.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S69 - S69
  • [9] The Association between Patient Reported Outcomes and Clinical Measures Among Rheumatoid Arthritis Patients: Analyses Using Phase 3 Clinical Trials of Upadacitinib
    Strand, Vibeke
    Damjanov, Nemanja
    Scoville, Craig
    Tundia, Namita
    Camp, Heidi S.
    Chen, Kun
    Suboticki, Jessica
    van Vollenhoven, Ronald
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [10] Perception and acceptance of intradermal influenza vaccination Patient reported outcomes from phase 3 clinical trials
    Reygrobellet, Camille
    Viala-Danten, Muriel
    Meunier, Juliette
    Weber, Francoise
    Van Hung Nguyen
    HUMAN VACCINES, 2010, 6 (04): : 336 - 345
12345